Climb Bio Shares Jump 17% After Phase 1 Data for CLYM116
CLYM Climb Bio Inc
$15.05 +1.55%
View chart & analysis → - 1Climb Bio (CLYM) shares rose 17% after the company released Phase 1 data for CLYM116, its candidate for IgA nephropathy.
- 2A single 320mg dose reduced IgA by 60–75% over 12 weeks, with a favorable tolerability profile and no serious adverse events.
- 3A Phase 2 trial is ongoing, with initial data expected in the first half of 2027 and a Phase 3 trial planned for the same year.
This 3-line summary is compiled from the report below.
Investor's Business Daily +1 View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.